Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
Authors: Philippe Autier, Peter Boyle
Journal: Annals of Internal Medicine (2018)

Letters17 April 2018Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO TrialsPhilippe Autier, MD and Peter Boyle, PhDPhilippe Autier, MDUniversity of Strathclyde, Lyon, France (P.A., P.B.)Search for more papers by this author and Peter Boyle, PhDUniversity of Strathclyde, Lyon, France (P.A., P.B.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0733 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Tsodikov and colleagues (1) present a complex reanalysis of the PLCO and ERSPC trials based on screening intensity. This factor in each of the 4 randomization groups was estimated using the MLT, which quantifies by how long the diagnosis of prostate cancer has been advanced. The variable of randomization group in Cox models was then replaced by the value of the MLT found for each group. We believe that this statistical approach is incorrect.We are aware of no other trial in which the variable of randomization group was replaced by one representing a value calculated according ...Reference1. Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167:449-55. [PMID: 28869989]. doi:10.7326/M16-2586 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Strathclyde, Lyon, France (P.A., P.B.)Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0733. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoReconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Alex Tsodikov , Roman Gulati , Eveline A.M. Heijnsdijk , Paul F. Pinsky , Sue M. Moss , Sheng Qiu , Tiago M. de Carvalho , Jonas Hugosson , Christine D. Berg , Anssi Auvinen , Gerald L. Andriole , Monique J. Roobol , E. David Crawford , Vera Nelen , Maciej Kwiatkowski , Marco Zappa , Marcos Luján , Arnauld Villers , Eric J. Feuer , Harry J. de Koning , Angela B. Mariotto , and Ruth Etzioni Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Join Y. Luh , Steven E. Finkelstein , Jeff M. Michalski , and Howard Sandler MD Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Philip C. Prorok and Anthony B. Miller Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Stuart G. Baker Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Shinkan Tokudome , Ryosuke Ando , and Shuji Hashimoto Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Alex Tsodikov , Roman Gulati , and Ruth Etzioni Metrics Cited byProstate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998–2017 17 April 2018Volume 168, Issue 8Page: 606KeywordsCancer detection and diagnosisCancer screeningConflicts of interestDisclosureHazard ratioMortalityProstate cancerRandomized trials ePublished: 17 April 2018 Issue Published: 17 April 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...